Beranda › Kanker Payudara Triple-Negatif › Michigan › Grand Rapids
Uji klinis Kanker Payudara Triple-Negatif di Grand Rapids, MI
15 studi untuk Kanker Payudara Triple-Negatif mencari peserta di lokasi sekitar Grand Rapids (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Menerima pesertaFase 3
- Cancer & Hematology Centers of Western Michigan ( Site 0026), Grand Rapids
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- South Texas Accelerated Research Therapeutics (START), Grand Rapids
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Menerima pesertaFase 1
- START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- BAMF Health, Grand Rapids
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Menerima pesertaFase 1
- BAMF Health, Grand Rapids
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
Menerima pesertaFase 1
- START Midwest, Grand Rapids
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Menerima pesertaFase 3
- Cancer and Hematology Centers of Western Michigan, Grand Rapids
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Menerima pesertaFase 1
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Research Site, Grand Rapids
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- START Midwest, Grand Rapids
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Menerima pesertaFase 1/2
- START Midwest, Grand Rapids
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Menerima pesertaFase 1
- BAMF Health, Grand Rapids
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- START Midwest, LLC, Grand Rapids
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Menerima pesertaFase 1
- START Midwest /ID# 248685, Grand Rapids
Uji klinis Kanker Payudara Triple-Negatif di kota lain
- Houston, TX42 studi
- New York City, NY31 studi
- Nashville, TN27 studi
- Los Angeles, CA26 studi
- Boston, MA26 studi
- San Antonio, TX22 studi
- St. Louis, MO21 studi
- Arlington, VA20 studi
- Atlanta, GA20 studi
- Dallas, TX18 studi
- Columbus, OH16 studi
- Chicago, IL16 studi
Studi lain di Grand Rapids
- Kanker Paru Non-Sel Kecil44 studi
- Kanker Kolorektal40 studi
- Kanker (semua jenis)28 studi
- Kanker Payudara26 studi
- Kanker Ovarium24 studi
- Kanker Metastatik22 studi
- Kanker Prostat19 studi
- Kanker Pankreas18 studi
- Kanker Lambung18 studi
- Kanker Endometrium18 studi
- Melanoma17 studi
- Karsinoma Sel Skuamosa Kepala dan Leher15 studi
Dari ClinicalTrials.gov, data diambil 7 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.